Coronary stents have landed in 23 provinces and municipalities after price cuts?

Yes. National Medical Protection Bureau news, as of January 9, the national organization of coronary stents centralized volume purchasing selected results in Beijing, Tianjin and other 23 provinces and municipalities officially landed in the implementation , the patients in these places with the collection of coronary stents after the collection of stents. The eight provinces and municipalities that have not landed have given a clear landing time, and all provinces nationwide have landed the implementation at the end of January.

The 10 selected varieties produced at the beginning of November 2020, from the average price of 13,000 yuan to about 700 yuan, a reduction of more than 90%, is expected to save 10.9 billion yuan of health insurance funds, the patient's out-of-pocket part will also be reduced.

Expanded

Reduced prices do not reduce the quality

For patients most concerned about the quality of the stent, the national organization of high-value medical supplies joint purchasing office director of the Tianjin Municipal Medical Protection Bureau, deputy director of the Zhang Tiejun, said, this set of mining has been targeted early! The "four-fold" safeguard measures, "the stability of the quality of the stent can be guaranteed".

The first safeguard is that as a "Class III medical device", any adjustment of raw materials and production process should be reported to the State Drug Administration for approval and strict inspection;

The second safeguard is that the state procurement adopts the "registration certificate". "

The third guarantee is that the competent authorities have acted quickly to deploy the whole process from production, sales, use, etc. to focus on supervision;

The fourth guarantee is the newly established pharmaceutical price and investment procurement credit evaluation system, product quality is linked to corporate credit evaluation, so the collection of stents

The fourth guarantee is the newly established pharmaceutical price and investment procurement credit evaluation system, which links product quality with enterprise credit evaluation.